These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 31066887)
1. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial. McIntyre RS; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Rosenblat JD; Brietzke E; Soczynska JK; Cosgrove VE; Miller S; Fischer EG; Kramer NE; Dunlap K; Suppes T; Mansur RB JAMA Psychiatry; 2019 Aug; 76(8):783-790. PubMed ID: 31066887 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial. Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. Lee Y; Mansur RB; Brietzke E; Carmona NE; Subramaniapillai M; Pan Z; Shekotikhina M; Rosenblat JD; Suppes T; Cosgrove VE; Kramer NE; McIntyre RS Brain Behav Immun; 2020 Aug; 88():631-639. PubMed ID: 32380271 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469 [TBL] [Abstract][Full Text] [Related]
5. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. Calabrese JR; Ketter TA; Youakim JM; Tiller JM; Yang R; Frye MA J Clin Psychiatry; 2010 Oct; 71(10):1363-70. PubMed ID: 20673554 [TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH; J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366 [TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). Young AH; McElroy SL; Bauer M; Philips N; Chang W; Olausson B; Paulsson B; Brecher M; J Clin Psychiatry; 2010 Feb; 71(2):150-62. PubMed ID: 20122369 [TBL] [Abstract][Full Text] [Related]
8. Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression. Mansur RB; Delgado-Peraza F; Subramaniapillai M; Lee Y; Iacobucci M; Rodrigues N; Rosenblat JD; Brietzke E; Cosgrove VE; Kramer NE; Suppes T; Raison CL; Chawla S; Nogueras-Ortiz C; McIntyre RS; Kapogiannis D Cells; 2020 Apr; 9(4):. PubMed ID: 32268604 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. van der Loos ML; Mulder PG; Hartong EG; Blom MB; Vergouwen AC; de Keyzer HJ; Notten PJ; Luteijn ML; Timmermans MA; Vieta E; Nolen WA; J Clin Psychiatry; 2009 Feb; 70(2):223-31. PubMed ID: 19200421 [TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression. Toniolo RA; Silva M; Fernandes FBF; Amaral JAMS; Dias RDS; Lafer B J Neural Transm (Vienna); 2018 Feb; 125(2):247-257. PubMed ID: 29177955 [TBL] [Abstract][Full Text] [Related]
12. Effect of Adjunctive Simvastatin on Depressive Symptoms Among Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. Husain MI; Chaudhry IB; Khoso AB; Kiran T; Khan N; Ahmad F; Hodsoll J; Husain MO; Naqvi HA; Nizami AT; Chaudhry N; Khan HA; Minhas F; Meyer JH; Ansari MA; Mulsant BH; Husain N; Young AH JAMA Netw Open; 2023 Feb; 6(2):e230147. PubMed ID: 36808239 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial. Lam RW; Levitt AJ; Levitan RD; Michalak EE; Cheung AH; Morehouse R; Ramasubbu R; Yatham LN; Tam EM JAMA Psychiatry; 2016 Jan; 73(1):56-63. PubMed ID: 26580307 [TBL] [Abstract][Full Text] [Related]
14. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
15. Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. Hellmann-Regen J; Clemens V; Grözinger M; Kornhuber J; Reif A; Prvulovic D; Goya-Maldonado R; Wiltfang J; Gruber O; Schüle C; Padberg F; Ising M; Uhr M; Friede T; Huber C; Manook A; Baghai TC; Rupprecht R; Heuser I JAMA Netw Open; 2022 Sep; 5(9):e2230367. PubMed ID: 36103181 [TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. Raison CL; Rutherford RE; Woolwine BJ; Shuo C; Schettler P; Drake DF; Haroon E; Miller AH JAMA Psychiatry; 2013 Jan; 70(1):31-41. PubMed ID: 22945416 [TBL] [Abstract][Full Text] [Related]
17. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Savitz JB; Teague TK; Misaki M; Macaluso M; Wurfel BE; Meyer M; Drevets D; Yates W; Gleason O; Drevets WC; Preskorn SH Transl Psychiatry; 2018 Jan; 8(1):27. PubMed ID: 29362444 [TBL] [Abstract][Full Text] [Related]
18. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. Suppes T; Kroger H; Pikalov A; Loebel A J Psychiatr Res; 2016 Jul; 78():86-93. PubMed ID: 27089521 [TBL] [Abstract][Full Text] [Related]
19. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Furey ML; Drevets WC Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Tohen M; Vieta E; Calabrese J; Ketter TA; Sachs G; Bowden C; Mitchell PB; Centorrino F; Risser R; Baker RW; Evans AR; Beymer K; Dube S; Tollefson GD; Breier A Arch Gen Psychiatry; 2003 Nov; 60(11):1079-88. PubMed ID: 14609883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]